伴有或不伴有勃起功能障碍的良性前列腺增生症的治疗管理选择：聚焦于他达拉非及患者考量因素
Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.
作者信息
Alsaikhan Bader, Alrabeeah Khalid, Carrier Serge
机构信息
McGill University Health Centre, Montreal, Quebec, QC, Canada.
出版信息
Int J Gen Med. 2014 Jun 12;7:271-6. doi: 10.2147/IJGM.S40216. eCollection 2014.
Abstract
Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age. Several studies have identified a true association between these two disorders. Basic research studies have shown a significant decrease in the nitric oxide/cyclic guanosine monophosphate pathway with age that leads to decreased relaxation of the bladder wall and prostate and worsening LUTS. In this review article, we will focus on the potential use and clinical significance of phosphodiesterase-5 inhibitors in the treatment of LUTS secondary to benign prostate hyperplasia.
摘要
下尿路症状（LUTS）和勃起功能障碍会随着年龄的增长而增加。多项研究已证实这两种疾病之间存在真正的关联。基础研究表明，随着年龄的增长，一氧化氮/环磷酸鸟苷途径显著减少，导致膀胱壁和前列腺松弛功能下降，进而使下尿路症状恶化。在这篇综述文章中，我们将重点关注磷酸二酯酶-5抑制剂在治疗良性前列腺增生继发的下尿路症状方面的潜在用途和临床意义。
相似文献
1
Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.
Int J Gen Med. 2014 Jun 12;7:271-6. doi: 10.2147/IJGM.S40216. eCollection 2014.
2
3
Tadalafil for the treatment of benign prostatic hyperplasia.
Expert Opin Pharmacother. 2019 Jun;20(8):929-937. doi: 10.1080/14656566.2019.1589452. Epub 2019 Mar 22.
4
5
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Eur Urol. 2016 Jul;70(1):124-133. doi: 10.1016/j.eururo.2015.12.048. Epub 2016 Jan 22.
6
Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
J Urol. 2014 Feb;191(2):405-11. doi: 10.1016/j.juro.2013.09.057. Epub 2013 Oct 1.
7
Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms.
Low Urin Tract Symptoms. 2012 Mar;4 Suppl 1:75-80. doi: 10.1111/j.1757-5672.2011.00121.x.
8
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
Int J Urol. 2017 Jun;24(6):412-424. doi: 10.1111/iju.13336. Epub 2017 Mar 22.
9
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19.
10
Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
J Sex Med. 2014 Feb;11(2):498-505. doi: 10.1111/jsm.12386. Epub 2013 Nov 13.
引用本文的文献
1
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Cochrane Database Syst Rev. 2018 Nov 16;11(11):CD010060. doi: 10.1002/14651858.CD010060.pub2.
2
The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review.
J Inflamm (Lond). 2015 Sep 15;12:54. doi: 10.1186/s12950-015-0099-7. eCollection 2015.
本文引用的文献
1
A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
J Sex Med. 2014 Jan;11(1):187-96. doi: 10.1111/jsm.12357. Epub 2013 Oct 25.
2
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
J Urol. 2014 Mar;191(3):727-33. doi: 10.1016/j.juro.2013.09.059. Epub 2013 Oct 2.
3
Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis.
Urol Int. 2013;91(1):10-8. doi: 10.1159/000351405. Epub 2013 Jun 25.
4
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19.
5
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity.
J Urol. 2013 Oct;190(4):1430-5. doi: 10.1016/j.juro.2013.03.112. Epub 2013 Mar 29.
6
Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.
Drugs Aging. 2012 Sep;29(9):771-81. doi: 10.1007/s40266-012-0010-7.
7
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25.
8
Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
Urology. 2012 Apr;79(4):875-82. doi: 10.1016/j.urology.2011.11.040. Epub 2012 Feb 14.
9
Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.
Handb Exp Pharmacol. 2011(202):527-42. doi: 10.1007/978-3-642-16499-6_23.
10
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
Neurourol Urodyn. 2011 Mar;30(3):292-301. doi: 10.1002/nau.20999. Epub 2011 Jan 31.
Zotero 插件